MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2026.02.058

Медицинская библиотека · Transplantation and cellular therapy · 2026

Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Gomez-Llobell Marina, Shouval Roni, Brown Samantha, Goan-Accav Noa, Devlin Sean, Corona Magdalena, Rejeski Kai, Rivas-Delgado Alfredo, Luna Alejandro, Luttwak Efrat, Raj Sandeep S, Alhomoud Mohammad, Sanz Jaime, Einarsdottir Sigrun, Marcus Ronit, Shimoni Avichai, Ringelstein-Harlev Shimrit, Khatib Hazim, Boardman Alexander P, Lue Jennifer, Dahi Parastoo, Lin Richard, Scordo Michael, Falchi Lorenzo, Shah Gunjan L, Palomba M Lia, Salles Gilles, Park Jae H, Beyar-Katz Ofrat, Avigdor Abraham, Perales Miguel-Angel

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

CAR T-cell therapy has transformed relapsed/refractory large B-cell lymphoma (LBCL) treatment, yet durable remissions remain challenging. In this retrospective multicenter study, 479 LBCL patients treated with commercial CD19 CAR-T products, axicabtagene ciloleucel (axi-cel, n = 262), tisagenlecleucel (tisa-cel, n = 131), and lisocabtagene maraleucel (liso-cel, n = 86), were evaluated using serial landmark analyses, with median follow-ups of 23, 34, and 16 months, respectively. Progression-free survival (PFS) was assessed at Day 28 and at 3, 6, 12, 18 and 24 months post-infusion to determine when relapse risk declines and sustained disease-free remission is achieved. Patients who attained a complete response (CR) at early time points had significantly improved PFS. In multivariable analyses, elevated pre-lymphodepletion lactate dehydrogenase (LDH) levels were independently associated with inferior PFS across several landmarks (HR 2.67, P < .001 at Day 28; HR 1.83, P = .044 at 3 months; HR 2.19, P = .016 at 6 months) and showed consistent association with inferior overall survival (OS) at these same time points. Cumulative relapse and non-relapse mortality (NRM) estimates supported the prognostic value of sustained CR. This landmark-based analysis advances understanding of durable remission kinetics following CAR T-cell therapy, indicating a trend toward cure, though longer follow-up is needed to confirm durable remission.

Для цитирования: Gomez-Llobell Marina, Shouval Roni, Brown Samantha, Goan-Accav Noa, Devlin Sean, Corona Magdalena, Rejeski Kai, Rivas-Delgado Alfredo, Luna Alejandro, Luttwak Efrat, Raj Sandeep S, Alhomoud Mohammad, Sanz Jaime, Einarsdottir Sigrun, Marcus Ronit, Shimoni Avichai, Ringelstein-Harlev Shimrit, Khatib Hazim, Boardman Alexander P, Lue Jennifer, Dahi Parastoo, Lin Richard, Scordo Michael, Falchi Lorenzo, Shah Gunjan L, Palomba M Lia, Salles Gilles, Park Jae H, Beyar-Katz Ofrat, Avigdor Abraham, Perales Miguel-Angel. Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.. Transplantation and cellular therapy. 2026. DOI: 10.1016/j.jtct.2026.02.058.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.